This article is more than 5 years old. Information may no longer be current.

Intravitreal implant for diabetic macular edema begins phase 1 trial

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

MINNEAPOLIS, Minn. — The first clinical implants of an intravitreal device for the management of diabetic macular edema have been completed as part of a phase 1 safety study, maker SurModics announced in a press release.

The I-vation intravitreal implant delivers drugs on a sustained release basis for more than 1 year, the company said in its release. It can be implanted in a minimally invasive procedure and may be removed once the drug has been fully released, SurModics added.

SurModics, based in Minneapolis, acquired the I-vation product when it bought InnoRx earlier this year. The I-vation implant was developed by Eugene de Juan Jr., MD, founder of InnoRx.